Dr. Mary Mooney

This innovative study aims to identify the unmet needs of women in menopause and their health research priorities, and potential solutions to optimise menopausal health. The transformative element is focused on co-creating with women and healthcare professionals, a blueprint for personalised health and management of menopausal symptoms. This blueprint will inform national and international policy for directing future menopausal services and research priorities.

The predominance of prior research has focused on the causes of delay. However, the question about the reasons patients may seek treatment early has not been addressed. We believe this is important to consider, with the goal of identifying what might support patients with decision-making in seeking early treatment, in the future. Over the past decade there has been a paucity of qualitative research undertaken in the early post-MI phase, either during or following hospitalisation, with many studies focusing on the negative aspects of pre-hospital delay. We propose to depart from these negative perspectives by illuminating and exploring those positive actions taken by patients in seeking help, which is something that is rarely highlighted. Therefore, the aim of this study is to explore, within four weeks of the event, patients" perceptions of the contributors to their treatment-seeking interval, among those who sought treatment early, when experiencing a myocardial infarction. To elucidate patients' perceptions of the contributors to prompt treatment-seeking behaviours and responses to symptoms during acute myocardial infarction. Aim: To elucidate patients' perceptions of the contributors to prompt treatment-seeking behaviours and responses to symptoms during acute myocardial infarction. Objectives " To describe patients" perceptions of those factors that contributed to prompt treatment-seeking behaviour during their myocardial infarction. " To elucidate the basic social processes that may help to explain prompt help-seeking behaviour in the presence of myocardial infarction.

The primary objective of the study is to test the effectiveness of a study-specific blood pressure (B/P) monitor, and a study-specific weighing scales, together with the fluid heart tracker app (triple pack) in patients with heart failure. The secondary objective is to qualitatively assess participants and healthcare providers" perceived usefulness and clinical acceptability of the triple pack.

In 2017 the primary care reimbursement service of Ireland approved the use of LCZ696 (which later became known as Entresto) to be used following strict guidelines for use in selected patients with HFrEF. For patients with HFrEF who do not meet the criteria for use of Entresto and who have a systolic BP>100mmHg and no history of angioedema a ACE inhibitor is recommended or ARB if intolerant to ACE inhibitor (Grade 1A recommendation see reference more details). This was following PARADIGM-HF trial (McMurray et all, 2014). The study found LCZ696 was superior to enalapril in reducing the risk of death and of hospitalisation for heart failure. The study found that by reducing the inhibition of both the angiotensin II inhibitor receptor and neprilysin with Entresto, it therefore reduced the risk of death from cardiovascular causes or hospitalisation for heart failure the ACE inhibitor. The LCZ696 was also superior to enalapril in reducing symptoms and physical limitations of heart failure. These robust findings provided strong evidence that combined inhibition of the angiotensin receptor and nepilysin is superior to inhibition of the renin-angiotensin system alone inpatient with chronic heart failure. This study will quantify the effects of Entresto in HF patients using secondary data analysis.

The main objective of CHLOE is to develop a unifying S&G-aware framework to investigate and understand CVD risk factors and development following a life course approach, from youth to menopause age, considering risk trajectories and underlying biological mechanisms following both classical epidemiological approaches and modern, data-driven and AI-enabled precision medicine approaches. This framework will allow to better understand CVD development and progression, derive women-specific risk scores and multimodal prediction models and design personalized prevention strategies based on actionable end-user digital tools. In doing so, CHLOE will adopt a life-course approach to women"s CVD understanding and prevention, interpreting women"s cardiovascular health as a dynamic process influenced by different interacting biological, environmental, lifestyle, psychosocial and clinical risk factors, including gender-related disparities, while considering different women-specific biological milestones for young and middle-age women, such as early exposure, younghood, pregnancy and the postpartum and menopause, that importantly shape CVD risk trajectories in women and may provide opportunities for early detection and intervention. The overarching goal is to reduce the burden of CVD in women in general, addressing urgent gaps and reducing S&G disparities in CVD prevention, diagnosis and management, and increase awareness on cardiovascular health and CVD prevention strategies in young women, where they can have important long-lasting societal impact.